PL3118223T3 - Przeciwciała anty-mif do stosowania do leczenia chorób zapalnych - Google Patents

Przeciwciała anty-mif do stosowania do leczenia chorób zapalnych

Info

Publication number
PL3118223T3
PL3118223T3 PL16183733T PL16183733T PL3118223T3 PL 3118223 T3 PL3118223 T3 PL 3118223T3 PL 16183733 T PL16183733 T PL 16183733T PL 16183733 T PL16183733 T PL 16183733T PL 3118223 T3 PL3118223 T3 PL 3118223T3
Authority
PL
Poland
Prior art keywords
inflammatory diseases
treating inflammatory
mif antibodies
anti mif
antibodies
Prior art date
Application number
PL16183733T
Other languages
English (en)
Inventor
Randolf Kerschbaumer
Friedrich Scheiflinger
Manfred Rieger
Michael Thiele
C. Geert Mudde
Jürgen Muellberg
Rene Hoet
Original Assignee
Baxalta Incorporated
Baxalta GmbH
Dyax Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Incorporated, Baxalta GmbH, Dyax Corporation filed Critical Baxalta Incorporated
Publication of PL3118223T3 publication Critical patent/PL3118223T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
PL16183733T 2008-01-04 2008-12-30 Przeciwciała anty-mif do stosowania do leczenia chorób zapalnych PL3118223T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US1898808P 2008-01-04 2008-01-04
US9468508P 2008-09-05 2008-09-05
PCT/EP2008/011146 WO2009086920A1 (en) 2008-01-04 2008-12-30 Anti mif antibodies
EP20120189220 EP2548890A1 (en) 2008-01-04 2008-12-30 Anti MIF antibodies
EP14163839.5A EP2754671B1 (en) 2008-01-04 2008-12-30 Anti MIF antibodies
EP16183733.1A EP3118223B8 (en) 2008-01-04 2008-12-30 Anti mif antibodies for use in treating inflammatory diseases
EP08869976.4A EP2231707B1 (en) 2008-01-04 2008-12-30 Anti mif antibodies

Publications (1)

Publication Number Publication Date
PL3118223T3 true PL3118223T3 (pl) 2021-04-06

Family

ID=40535633

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08869976T PL2231707T3 (pl) 2008-01-04 2008-12-30 Przeciwciała przeciwko MIF
PL16183733T PL3118223T3 (pl) 2008-01-04 2008-12-30 Przeciwciała anty-mif do stosowania do leczenia chorób zapalnych

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08869976T PL2231707T3 (pl) 2008-01-04 2008-12-30 Przeciwciała przeciwko MIF

Country Status (23)

Country Link
US (3) US20090220521A1 (pl)
EP (4) EP2754671B1 (pl)
JP (1) JP5502752B2 (pl)
KR (2) KR20160105943A (pl)
CN (2) CN103724430B (pl)
AU (1) AU2008346517B2 (pl)
BR (1) BRPI0821682A2 (pl)
CA (1) CA2711029A1 (pl)
CY (1) CY1117302T1 (pl)
DK (1) DK2231707T3 (pl)
ES (3) ES2791333T3 (pl)
HK (1) HK1147762A1 (pl)
HR (1) HRP20150224T1 (pl)
IL (1) IL206715A (pl)
MX (1) MX2010007406A (pl)
NZ (3) NZ586600A (pl)
PL (2) PL2231707T3 (pl)
PT (1) PT2231707E (pl)
RS (1) RS53906B1 (pl)
RU (2) RU2509777C2 (pl)
SI (1) SI2231707T1 (pl)
WO (1) WO2009086920A1 (pl)
ZA (1) ZA201004973B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008346517B2 (en) * 2008-01-04 2013-12-05 Baxalta GmbH Anti MIF antibodies
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
AU2012320597C1 (en) * 2011-10-07 2015-10-15 Baxalta GmbH oxMIF as a diagnostic marker
WO2013050457A1 (en) 2011-10-07 2013-04-11 Baxter Healthcare S.A. Characterization of cho-mif gene and protein, and use thereof
AU2013203957B9 (en) * 2012-04-16 2015-10-15 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Glucocorticoids
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
CN105452867A (zh) * 2012-07-10 2016-03-30 巴克斯特保健股份有限公司 抗-mif的免疫组织化学
JP2016502669A (ja) * 2012-12-07 2016-01-28 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 抗ｍｉｆ抗体細胞遊走アッセイ
US10613100B2 (en) * 2014-01-03 2020-04-07 Baxalta Incorporated Anti-MIF immunohistochemistry
EP3183581A1 (en) 2014-08-22 2017-06-28 Baxalta GmbH Detection of cho-mif contaminations
WO2016156489A1 (en) 2015-03-31 2016-10-06 Baxalta GmbH Dosage regimen for anti-mif antibodies
US20180155419A1 (en) 2015-05-18 2018-06-07 Baxalta GmbH Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
CN109868311B (zh) * 2017-12-01 2023-10-20 上海市精神卫生中心 Mif及其预测二代抗精神病药物诱导的代谢不良反应的应用
KR20210018800A (ko) * 2018-06-07 2021-02-18 온코원 리서치 앤드 디벨롭먼트 게엠베하 암 치료를 위한 항-oxMIF/항-CD3 항체
EP3757252B1 (en) 2019-06-28 2022-03-30 Walter Ag A coated cutting tool
AU2020397229A1 (en) 2019-12-06 2022-06-30 Oncoone Research & Development Gmbh Anti-oxMIF/anti-CD3 bispecific antibody constructs
EP4222170B1 (en) 2020-10-02 2024-03-20 OncoOne Research & Development GmbH Improved anti-oxmif antibodies with reduced aggregation potential and reduced hydrophobicity
EP4288118A1 (en) 2021-02-03 2023-12-13 OncoOne Research & Development GmbH Anti-oxmif radioimmunoconjugate
WO2023031397A1 (en) 2021-09-03 2023-03-09 Oncoone Research & Development Gmbh IMPROVED Fc SILENCED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY
WO2023133360A2 (en) * 2022-01-10 2023-07-13 Phenomic Ai Anti-collagen triple helix repeat containing 1 (cthrc1) antibodies and methods of using the same
CN114573693A (zh) * 2022-04-25 2022-06-03 中国人民解放军陆军军医大学 一种听觉发育中免疫调节分子mif抗体制备方法
CN115814069B (zh) * 2022-10-31 2023-07-21 四川大学华西医院 Mif基因敲除的肿瘤细胞在制备肿瘤疫苗中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645493B1 (en) 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US6774227B1 (en) * 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
JPH0977799A (ja) * 1995-09-13 1997-03-25 Sapporo Immuno Diagnostic Lab:Kk ヒト−マクロファージ遊走阻止因子（ヒト−ｍｉｆ）に対するモノクローナル抗体および該抗体を産生するハイブリドーマ
PT1156823E (pt) * 1999-02-12 2009-01-08 Scripps Research Inst Métodos para tratamento de tumores e metástases utilizando uma combinação de terapias anti-angiogénicas e imunitárias
US20030235584A1 (en) 2000-02-28 2003-12-25 Kloetzer William S. Method for preparing anti-MIF antibodies
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CN100457895C (zh) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
AU2008346517B2 (en) * 2008-01-04 2013-12-05 Baxalta GmbH Anti MIF antibodies

Also Published As

Publication number Publication date
EP3118223B8 (en) 2020-04-15
IL206715A (en) 2015-06-30
US20090220521A1 (en) 2009-09-03
BRPI0821682A2 (pt) 2015-06-16
EP2231707A1 (en) 2010-09-29
EP2754671B1 (en) 2016-12-21
EP2231707B1 (en) 2014-12-24
WO2009086920A1 (en) 2009-07-16
EP2754671A2 (en) 2014-07-16
SI2231707T1 (sl) 2015-04-30
NZ586600A (en) 2012-05-25
PL2231707T3 (pl) 2015-05-29
US8668909B2 (en) 2014-03-11
US20100260768A1 (en) 2010-10-14
MX2010007406A (es) 2010-10-05
EP3118223A1 (en) 2017-01-18
EP2754671A3 (en) 2015-07-08
ZA201004973B (en) 2011-03-30
IL206715A0 (en) 2010-12-30
ES2623653T3 (es) 2017-07-11
CY1117302T1 (el) 2017-04-26
NZ611117A (en) 2014-10-31
HRP20150224T1 (en) 2015-06-05
ES2531629T3 (es) 2015-03-18
EP2548890A1 (en) 2013-01-23
CN103724430A (zh) 2014-04-16
AU2008346517A1 (en) 2009-07-16
ES2791333T3 (es) 2020-11-03
RU2509777C2 (ru) 2014-03-20
NZ596409A (en) 2013-05-31
KR20100102197A (ko) 2010-09-20
PT2231707E (pt) 2015-03-25
JP2011510616A (ja) 2011-04-07
DK2231707T3 (en) 2015-03-02
JP5502752B2 (ja) 2014-05-28
US20150023978A1 (en) 2015-01-22
RU2010132647A (ru) 2012-02-10
RS53906B1 (en) 2015-08-31
CN103724430B (zh) 2016-09-21
CA2711029A1 (en) 2009-07-16
KR101654678B1 (ko) 2016-09-08
AU2008346517B2 (en) 2013-12-05
CN101983207B (zh) 2016-01-20
HK1147762A1 (en) 2011-08-19
RU2013153592A (ru) 2015-06-10
CN101983207A (zh) 2011-03-02
EP3118223B1 (en) 2020-02-19
KR20160105943A (ko) 2016-09-07

Similar Documents

Publication Publication Date Title
PL3118223T3 (pl) Przeciwciała anty-mif do stosowania do leczenia chorób zapalnych
IL257418A (en) Methods for treating addiction
HK1217722A1 (zh) 人抗α-突觸核蛋白抗體
IL241091A0 (en) Antibodies to fcrn and their use
EP2279003A4 (en) ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP2170950A4 (en) ANTI-IL-20 ANTIBODIES AND ITS USE IN THE TREATMENT OF INFLAMMATORY DISEASES ASSOCIATED WITH IL-20
ZA201001789B (en) Composition and methods for use for antibodies against sclerostin
EP2069784A4 (en) IL-33 IN INFLAMMATORY DISEASE
IL209216A0 (en) Methods for preventing and treating neurodegenerative diseases
IL201552A0 (en) Antibodies against il-25
HK1154022A1 (en) Antibodies against il-25 il-25
GB0807018D0 (en) Antibodies and treatment
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
PL2617734T3 (pl) Ludzkie przeciwciała przeciwko TSHR
GB0815788D0 (en) Therapeutic antibodies
EP2324059A4 (en) THERAPEUTIC ANTI-PAMP ANTIBODIES
GB0821958D0 (en) Camera for use in vehicle
GB0818713D0 (en) Substances useful for treating diseases
IL213399B (en) Hodah extraction for use in the treatment of liver diseases
GB0821274D0 (en) Compounds for use in therapy
ZA201000867B (en) Methods for treating dependence